RxDoctor Payments Data

Martha Preciado, MD

Cardiovascular Disease · Los Angeles, CANPI 1144244211

Payments from drug & device makers

$4,654in general payments, 2019–2025

Across 206 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$944
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$618
  • Actelion Pharmaceuticals US, Inc.$329
  • Bayer$310
  • Boston Scientific$159
  • plus $622 from 10 others

What the payments were for

  • Food & beverage$4,639100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,654 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,554,976
Medicare patients
568
Services billed
16,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$197,274
AdempasRiociguat14$161,292
EntrestoSacubitril/Valsartan59$71,385
XareltoRivaroxaban44$56,059
BrilintaTicagrelor31$29,625
Ranolazine ErRanolazine98$14,678
Metoprolol Succinate388$5,369
Nitroglycerin286$3,168
Carvedilol229$1,888
Isosorbide Mononitrate ErIsosorbide Mononitrate118$1,730
ClopidogrelClopidogrel Bisulfate126$1,707
Amiodarone Hcl34$1,654
Atorvastatin Calcium192$1,623
Losartan Potassium218$1,605
Furosemide232$1,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$140$197,274181 claims
BayerAdempas$310$161,29214 claims
NovartisEntresto$146$71,38559 claims
Johnson & JohnsonXarelto$60$56,05944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →